---
title: "Mabwell wins China NMPA IND clearance for LILRB4/CD3 bispecific 6MW5311 in blood cancers"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290619996.md"
description: "Mabwell Bioscience has received IND clearance from China's NMPA to initiate clinical trials for 6MW5311, a LILRB4/CD3 bispecific antibody targeting blood cancers like AML and multiple myeloma. This marks the first global LILRB4/CD3 T-cell engager to secure such approval, following prior FDA clearance."
datetime: "2026-06-24T00:00:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290619996.md)
  - [en](https://longbridge.com/en/news/290619996.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290619996.md)
generator: "portal-rs"
---

# Mabwell wins China NMPA IND clearance for LILRB4/CD3 bispecific 6MW5311 in blood cancers

-   Mabwell won China NMPA clearance to start clinical trials of 6MW5311, a LILRB4/CD3 T-cell engager bispecific antibody. \* The candidate targets blood cancers, including AML, CMML, and multiple myeloma. \* Mabwell said 6MW5311 is the first LILRB4/CD3 TCE globally to secure clinical trial approval, following earlier FDA clearance. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mabwell (Shanghai) Bioscience Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606232000PR\_NEWS\_USPR\_\_\_\_\_CN90191) on June 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [688062.CN](https://longbridge.com/en/quote/688062.CN.md)
- [02493.HK](https://longbridge.com/en/quote/02493.HK.md)

## Related News & Research

- [Mabwell Sets Board Meeting to Approve 2026 Interim Results](https://longbridge.com/en/news/296331890.md)
- [Mabwell Wins NMPA Nod to Test Novel Autoimmune Antibody 9MW5211 in Vitiligo](https://longbridge.com/en/news/292766513.md)
- [Laekna enrolls first patient in China Phase I trial of cancer drug candidate LAE118](https://longbridge.com/en/news/297573070.md)
- [Oryzon Genomics wins US notice of allowance for iadademstat-gilteritinib AML patent application](https://longbridge.com/en/news/297475261.md)
- [AI turns up a promising finding in cancer data that researchers hadn’t noticed for years](https://longbridge.com/en/news/297215988.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**